Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a study titled ‘A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn’s Disease for 3 Years in Real-world Clinical Practice (UPlift).’ The study aims to evaluate the safety and effectiveness of upadacitinib in treating moderate to severe Crohn’s Disease (CD) in real-world settings, focusing on the speed of onset and durability of its effects.
The intervention being tested is upadacitinib, a drug already approved for CD treatment. Participants will receive the medication as prescribed by their doctors, following local guidelines, with no additional burden expected for participants.
This observational study follows a cohort model with a prospective time perspective. It is designed to observe the outcomes of upadacitinib treatment in a real-world clinical setting over three years, without specific allocation or masking procedures.
The study began on February 19, 2024, with an active, not recruiting status as of the last update on July 16, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
The update on this study could influence AbbVie’s stock performance positively, as successful results might enhance investor confidence and market position. The study’s outcomes could also impact the competitive landscape in the treatment of Crohn’s Disease, with potential implications for other pharmaceutical companies.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.